Inhale+

Company Description

Who We Are At Inhale+, we are redefining neonatal respiratory care with a paradigm shifting approach to inhalation therapy for preterm infants. Our team combines deep expertise in inhalation science, medical technology, and clinical application, focusing on delivering solutions to address critical healthcare needs for the most vulnerable patients. What is the Problem Every year, 14 million babies are born prematurely, and many suffer from severe respiratory distress. Current inhalation therapies are often ineffective due to low delivery efficiency, meaning infants receive insufficient medication. This limitation often necessitates a shift to invasive, high-risk interventions, which come with significant side effects and can result in long-term health complications. How We Solve It Inhale+ has developed a breakthrough, patent-protected inhalation add-on system that optimizes medication delivery directly to the lungs. This non-invasive approach enables efficient, targeted treatment at therapeutic levels, reducing the need for invasive procedures and minimizing side effects. Our technology supports early, preventative care, which is essential for improving outcomes in neonatal respiratory treatment. Current Status With successful lab trials completed, showing an improvement of 320% compared to the current inhalation standards, we are gearing up for our first clinical proof-of-concept trial in 2025. Backed by experts in neonatology and pulmonology, Inhale+ is well-positioned to address a vast unmet medical need and market to establish a new standard in neonatal care. We're currently at the seed stage, funded through non-dilutive sources until early 2026, and planning to initiate an investment round in mid/late 2025. We’d welcome the opportunity to connect beforehand.